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Abstract 1 
 2 
Background: Dyspnea is the impairing cardinal symptom in COPD, but the underlying brain 3 
mechanisms and their relationships to clinical patient characteristics are widely unknown. 4 
This study compared neural responses to the perception and anticipation of dyspnea between 5 
patients with stable moderate-to-severe COPD and healthy controls. Moreover, associations 6 
between COPD-specific brain activation and clinical patient characteristics were examined.  7 
Methods: During functional magnetic resonance imaging, dyspnea was induced in patients 8 
with stable moderate-to-severe COPD (n = 17) and healthy control subjects (n = 21) by 9 
resistive-loaded breathing. Blocks of severe and mild dyspnea were alternating, with each 10 
block being preceded by visually cued anticipation phases.  11 
Results: During the perception of increased dyspnea, both patients and controls showed 12 
comparable brain activation in common dyspnea-relevant sensorimotor and cortico-limbic 13 
brain regions. During the anticipation of increased dyspnea, patients showed higher activation 14 
in hippocampus and amygdala than controls which was significantly correlated with reduced 15 
exercise capacity, reduced health-related quality of life, and higher levels of dyspnea and 16 
anxiety.  17 
Conclusions: This study suggests that patients with stable moderate-to-severe COPD show 18 
higher activation in emotion-related brain areas than healthy controls during the anticipation, 19 
but not during the actual perception of experimentally induced dyspnea. These brain 20 
activations were related to important clinical characteristics and might contribute to an 21 
unfavourable course of the disease via maladaptive psychological and behavioural 22 
mechanisms.  23 
 24 
Abstract word count: 220 25 
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1. Introduction 1 
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent and debilitating respiratory 2 
disease, characterized by persistent and usually progressive airflow limitation (GOLD, 2017; 3 
O’Donnell et al., 2007). Dyspnea is the cardinal respiratory symptom of COPD, causing 4 
significant reductions in patients’ exercise capacity and quality of life, and is frequently linked 5 
to comorbid anxiety and depression (GOLD, 2017; Martínez Francés et al., 2008; Maurer et 6 
al., 2008; Roche, 2009; Schlecht et al., 2005; Waschki et al., 2015; Yohannes and 7 
Alexopoulos, 2014). Dyspnea is usually experienced as highly aversive and threatening 8 
(American Thoracic Society, 1999; Parshall et al., 2012). Consequently, many patients avoid 9 
situations associated with dyspnea, especially physical activity (O’Donnell, 2006). This 10 
maladaptive avoidance behavior results in progressive deconditioning, ultimately increasing 11 
dyspnea at lower activity levels and contributing to disease progression (Reardon et al., 2006; 12 
Troosters et al., 2013; Waschki et al., 2015). In particular, the fearful anticipation of dyspnea 13 
is suggested to play a key role within this spiral of decline (Hayen et al., 2013). 14 
The brain mechanisms underlying the perception and anticipation of dyspnea are still poorly 15 
understood. Previous neuroimaging studies in healthy volunteers have identified multiple 16 
dyspnea-related brain areas, presumably related to different aspects of dyspnea. 17 
Somatosensory and motor aspects are thought to be processed by sensorimotor areas (e.g. 18 
SM1, SII), while affective-motivational aspects are processed by cortico-limbic areas 19 
including anterior insula, anterior cingulate cortex (ACC), hippocampus, prefrontal cortex 20 
(PFC), and amygdala (Davenport and Vovk, 2009; Evans, 2010; von Leupoldt and Dahme, 21 
2005). Preliminary findings suggest an involvement of several of these areas such as the 22 
insula, amygdala, ACC and the periaqueductal gray (PAG) during the fearful anticipation of 23 
impending dyspnea (Faull et al., 2016; Stoeckel et al., 2016; Stoeckel et al., 2015). This 24 
converges with studies on other aversive states, e.g. fear, aversive learning, and pain, 25 
reporting activation in similar cortico-limbic structures (Apkarian et al., 2005; Peyron et al., 26 
2000; Sehlmeyer et al., 2009; Wiech and Tracey, 2013). Unfortunately, neuroimaging studies 27 
with high spatial resolution (e.g. functional magnetic resonance imaging [fMRI]) on the 28 
anticipation and perception of dyspnea in COPD patients are widely absent, which greatly 29 
limits our understanding of the potential contribution of disease-specific brain mechanisms to 30 
the patients’ burden.  31 
However, COPD-specific brain mechanisms due to chronic dyspnea experiences seem highly 32 
plausible (Herigstad et al., 2011). For example, contemporary models on the effects of chronic 33 
pain suggest that brain activation in pain patients shifts with chronicity from sensory to 34 
emotion-related areas, leading to increased activation preferentially in cortico-limbic 35 
structures (Apkarian et al., 2011; Mansour et al., 2014). Moreover, enhanced activation was 36 
recently demonstrated in emotion-related brain areas (i.e., PFC, ACC) of COPD patients 37 
while reading dyspnea-related statements (Herigstad et al., 2015).  38 
This fMRI-study aimed (1) to compare brain activation during the perception and anticipation 39 
of resistive-load induced increased dyspnea between patients with COPD and healthy control 40 
subjects and (2) to evaluate potential associations with patient characteristics. Analogous to 41 
findings on chronic pain (Apkarian et al., 2005, 2011; Baliki and Apkarian, 2015; Mansour et 42 
al., 2014), we hypothesized that during dyspnea perception, both groups activate similar 43 
dyspnea-relevant brain areas, with patients showing higher activation in cortico-limbic 44 
structures. Based on findings on fear, aversive learning, and dyspnea anticipation (Faull et al., 45 
2016; Sehlmeyer et al., 2009; Stoeckel et al., 2015; Wiech and Tracey, 2013), we further 46 
hypothesized that patients show enhanced activation in emotion-related brain areas during 47 
dyspnea anticipation.  48 
 49 
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 1 
2. Methods 2 
2.1. Participants 3 
Seventeen outpatients with stable (no exacerbation within the last year) moderate-to-severe 4 
COPD (GOLD stage 2 and 3) were recruited at a Pulmonary Research Institute at LungClinic 5 
Grosshansdorf, Grosshansdorf, Germany (14 patients) and an outpatient pulmonary 6 
rehabilitation centre (three patients before start of the rehabilitation program; Atem-Reha 7 
GmbH, Hamburg, Germany). The control group consisted of 21 individuals, recruited from 8 
the database of the Pulmonary Research Institute and was matched for age, sex, and body-9 
mass-index. All subjects participated in a previous study on structural brain changes in COPD 10 
(Esser et al., 2015). This study was approved by the ethics committees of the Medical 11 
Associations Hamburg (PV3006) and Schleswig-Holstein (IV/EK/122/08), and was 12 
conducted according to the Declaration of Helsinki. Written informed consent was obtained 13 
from each participant prior to testing 14 
Post-bronchodilator lung function (forced expiratory volume in 1s, FEV1; forced vital 15 
capacity, FVC) was measured using standard spirometry (Miller et al., 2005), based on 16 
established reference values (Quanjer et al., 1993). All control subjects had normal lung 17 
function (FEV1%pred > 80%; FEV1/FVC > 0.7) and no history of respiratory disease. All 18 
participants were screened using a standardized diagnostic interview to exclude psychiatric or 19 
neurological disorders (First et al., 1996). Furthermore,  participants completed the Hospital 20 
Anxiety and Depression Scale (HADS) to assess individual levels of anxiety and depression 21 
(Herrmann et al., 1995). In patients, further clinical characteristics were collected including 22 
exercise capacity (6-min-walk distance, 6MWD) (ATS Committee on Proficiency Standards 23 
for Clinical Pulmonary Function Laboratories, 2002), disease-specific quality of life (St. 24 
George’s Respiratory Questionnaire, SGRQ) (Jones et al., 1992), and degree of dyspnea 25 
during daily activities (modified Medical Research Council Dyspnea Scale, mMRC) (Bestall 26 
et al., 1999). 27 
 28 
2.2. Apparatus and respiratory parameters 29 
Participants breathed through a face mask, connected to an MR-compatible 30 
pneumotachograph (ZAN 600 unit, ZAN Messgeräte GmbH, Oberhulba, Germany) ending in 31 
a two-way non-rebreathing valve. A 2.6 m tube (diameter: 3.5 cm) was permanently 32 
connected to the inspiratory port of the valve, while the expiratory port was left free. This 33 
enabled the easy introduction and removal of MR-compatible, flow-resistive loads of variable 34 
magnitudes at the distal end of the tube. These loads (in-house manufactured) consisted of 35 
MR-compatible resistive screens of different porosity, which are permanently mounted in 36 
hard plastic casings. Each of these loads provides a known, calibrated resistance to the 37 
inspiratory air flow during loaded conditions, which is depending on the porosity of the 38 
screens (ie, the lower the porosity, the higher the resistance). Respiratory parameters including 39 
partial pressure of end-tidal CO2 (PETCO2), peak inspiratory pressure (PI), tidal volume (VT), 40 
breathing frequency (f), minute ventilation (VE), and inspiratory time (TI) were measured 41 
continuously. 42 
 43 
2.3. Experimental protocol 44 
One day prior to MRI testing, each subject was placed in a supine position (outside the 45 
scanner) and presented with different inspiratory loads of increasing magnitude. Each load 46 
was presented for 24s and subsequently rated with regard to dyspnea intensity using a Borg 47 
Scale (0 = ‘not noticeable’ to 10 = ‘maximally imaginable’). The sensation of dyspnea was 48 
explained as ‘uncomfortable or difficult breathing’ to our participants. Load magnitude was 49 
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increased until subjects reliably reported a sensation of ‘severe’ dyspnea (Borg Score > 5). 1 
That load was then used to induce severe dyspnea during scanning. For the mild dyspnea 2 
condition, the smallest load that was reliably rated as different from unloaded breathing was 3 
used.  4 
On the day of MRI scanning and after completing the questionnaires, participants were 5 
familiarized with the experimental design and set-up to avoid unintended learning processes 6 
during MRI data acquisition. Therefore, each subject underwent a computer-based 7 
standardized instruction, including explicit details on the associations between visual cues and 8 
experimental conditions, outside the scanner. Participants learned the association between 9 
different colors of the fixation cross indicating ‘mild’ and ‘severe’ load condition and changes 10 
in the thickness of fixation crosses used to differentiate between unloaded anticipation (thin 11 
cross) and loaded breathing (thick cross) periods. Furthermore, subjects were acquainted with 12 
the button response system used for Borg Scale ratings. Then, participants were connected to 13 
the breathing circuit and entered the scanner. Visual cues and Borg Scales were projected into 14 
the scanner bore via a mirror system, using Presentation software (Neurobehavioral Systems, 15 
Inc., Albany, CA). A test run allowed subjects to familiarize themselves with the button-box 16 
response system and all cues and scales.  17 
During MRI scanning, ten blocks of mild dyspnea and ten blocks of severe dyspnea were 18 
presented, each lasting 24s. In a fixed order, each mild dyspnea condition was followed by a 19 
severe dyspnea condition. Each loaded dyspnea condition was preceded by a 6s visually cued, 20 
unloaded anticipation period signaling with 100% contingency the upcoming load condition. 21 
Each loaded condition was followed by Borg Scale ratings of dyspnea intensity and 22 
unpleasantness, presented in randomized order. Borg Scale ratings lasted approximately 20 s 23 
and served to recover from loaded breathing as well as to re-establish baseline breathing 24 
before the next load condition. All experimental events and Borg Scale ratings were recorded 25 
via the Presentation software. (For a diagram of scanning protocol, see Figure 1). 26 
 27 
##### Figure 1. ##### 28 
 29 
2.4. Data analysis 30 
Respiratory parameters and Borg Scale ratings were averaged across respective experimental 31 
conditions and analyzed with SPSS Statistics 22 software (SPSS Inc., Chicago, IL), using a 32 
significance level of p < .05. We employed two-sample t-tests, Mann-Whitney-U-tests (non-33 
normal distributions), and χ2-tests (frequency data). 34 
MRI data were obtained on a 3T Magnetom-TRIO System (Siemens, Erlangen, Germany) 35 
using a 32-channel head coil. Functional MRI scans were acquired with an echo planar 36 
imaging T2*-sensitive sequence (48 contiguous axial slices in descending order, 2mm slice 37 
thickness with 1mm gap, TR = 2870ms, TE = 25ms, flip angle = 80°, field of view = 38 
208×208mm). After the fMRI-measurement, we collected a high-resolution T1-weighted 39 
structural brain image (MP-RAGE sequence, 1 mm isotropic voxel size, 240 slices). fMRI 40 
data preprocessing and statistical analysis was carried out using SPM8 (Statistical Parametric 41 
Mapping, www.fil.ion.ucl.ac.uk/spm) within Matlab2013a (The MathWorks, Inc., Natick, 42 
Massachusetts, United States). The first two blocks of each condition were excluded from the 43 
analysis to guarantee full adaptation to scanner environment and experimental conditions. All 44 
images were unwarped and realigned to the first image, coregistered to the individual high 45 
resolution T1 structural image, normalized to the standard template, and finally smoothed 46 
with an isotropic full-width at half-maximum Gaussian kernel of 8 mm. Severe dyspnea 47 
conditions were contrasted with mild dyspnea conditions rather than resting baseline 48 
conditions in order to guarantee that attention is similarly focused to the respiratory sensations 49 
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in both contrasted conditions and not free-floating as in rest conditions, which could have 1 
biased brain activation patterns. Additionally, some individuals might have experienced rest 2 
conditions as relieving compared to the more aversive character of the other conditions, which 3 
could have resulted in confounding relief-related brain activations instead of non-stimulus 4 
resting state activation patterns. 5 
On single-subject level, the statistical model included regressors for cue mild dyspnea, mild 6 
dyspnea, cue severe dyspnea, severe dyspnea, and ratings. Mean global signal intensity of 7 
each volume and PETCO2 time-logged to the beginning of each scan were included as 8 
covariates-of-no-interest, to correct for a potential effect of respiratory fluctuations on brain 9 
response. To compare individual results on group-level, contrasts for the perception of 10 
increased dyspnea [severe vs. mild dyspnea] and for the anticipation of increased dyspnea 11 
[cue mild vs. cue severe dyspnea] were created for each participant to calculate separate one-12 
sample t-tests for the patient and control group. A conjunction null analysis tested for brain 13 
areas showing shared significant activation between both groups. Group differences in neural 14 
activation for the perception and anticipation of increased dyspnea were tested with two-15 
sample t-tests. Here, smoking status (i.e. current, former, and never smoker) was included as 16 
covariate-of-no-interest. 17 
Differences in neural activation were accepted as significant if exceeding a threshold of p < 18 
.05 after whole-brain family-wise error correction (FWE) or family-wise error correction 19 
within predefined regions-of-interest (ROI). ROIs were based on previous results on the 20 
neural processing of dyspnea (Davenport and Vovk, 2009; Evans, 2010; Herigstad et al., 21 
2011), pain (Apkarian et al., 2005; Peyron et al., 2000), fear and aversive learning (Sehlmeyer 22 
et al., 2009; Wiech and Tracey, 2013), and included primary sensorimotor cortex (SM1), 23 
secondary somatosensory cortex (SII)/operculum, supplementary motor area (SMA), insula, 24 
ACC, thalamus, PFC, hippocampus, amygdala, and midbrain/PAG. Bilateral masks were 25 
generated from the automated anatomical labeling (AAL) template (Tzourio-Mazoyer et al., 26 
2002). For display purposes, we used a threshold of p uncorrected < .001 for all figures. 27 
Associations of brain activation with patient characteristics (disease duration; exercise 28 
capacity, 6MWD; quality of life, SGRQ; level of dyspnea, mMRC; and HADS anxiety and 29 
depression scores) were examined by off-line partial correlation analyses (controlled for 30 
smoking status).  31 
 32 
 33 
3. Results 34 
3.1. Participants 35 
As expected, patients showed significantly lower lung function and a greater proportion of 36 
current and former smokers compared to controls. There were no significant group differences 37 
regarding sex, age, height, weight, body-mass-index, and HADS scores. Furthermore, none of 38 
the participants showed clinically relevant HADS depression or anxiety scores. Patients with 39 
COPD had a relatively preserved 6MWD and minor exertional dyspnea according to the 40 
mMRC grades (Table 1). 41 
 42 
 43 
##### Table 1. ##### 44 
 45 
 46 
3.2. Dyspnea ratings  47 
Borg Scale ratings confirmed successful induction of mild and severe dyspnea. Ratings for 48 
dyspnea intensity and unpleasantness were significantly higher for the severe compared to the 49 
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mild dyspnea condition without significant differences between groups. Although patients 1 
reported slightly higher intensity and unpleasantness of mild dyspnea (most likely reflecting 2 
the chronic respiratory impairments in these patients), the increases from mild to severe 3 
dyspnea conditions (i.e. Δ intensity and Δ unpleasantness) were comparable between groups 4 
(Table 2). 5 
 6 
##### Table 2. ##### 7 
 8 
 9 
3.3. Respiratory parameters 10 
Both groups showed comparable, mildly hypocapnic breathing patterns during the perception 11 
(severe vs. mild dyspnea) and anticipation (cue severe vs. cue mild dyspnea) of dyspnea 12 
(Supplementary data sheet: Table S1). Although patients compared to controls demonstrated 13 
different absolute values of breathing frequency, minute ventilation, and inspiratory time 14 
throughout experimental conditions, the differences in respiratory parameters (i.e. Δ values; 15 
Table 3) were comparable between groups, suggesting comparable respiratory changes in 16 
both patients and controls. (See Supplementary data sheet, for more detailed information on 17 
respiratory parameters). 18 
 19 
 20 
##### Table 3. ##### 21 
 22 
 23 
3.4. Functional imaging data 24 
3.4.1. Perception of dyspnea  25 
One-sample within group t-tests for [severe vs. mild dyspnea] showed a widely comparable 26 
pattern of brain activation in both groups during the perception of increased dyspnea (Figure 27 
2A, 2B). This included areas related to sensorimotor processes (i.e. SM1, SII/operculum, 28 
SMA, and thalamus) and related to emotional/cognitive processing, such as insula, ACC, and 29 
PFC (Table 4 for patient group; see Supplementary data sheet for control group: Table S2). 30 
The conjunction analysis confirmed these findings by demonstrating a massive overlap of 31 
neural activation patterns between the patient and control group (Figure 2C, and 32 
Supplementary data sheet: Table S3). Notably, two-sample t-tests revealed no group 33 
differences in brain activation during increased dyspnea perception, i.e. neither enhanced nor 34 
reduced activation was observed in patients as compared to control subjects. 35 
 36 
 37 
##### Figure 2. ##### 38 
 39 
##### Table 4. ##### 40 
 41 
 42 
 43 
 44 
3.4.2. Anticipation of dyspnea  45 
One-sample t-tests for [cue severe vs. cue mild dyspnea] showed no statistically significant 46 
brain activation in any of the two groups, neither in the whole-brain nor in the ROI-based 47 
approach. However, two-sample t-tests revealed significantly higher neural activation in the 48 
right amygdala (peak: x, y, z = 36, 2, -24, Z = 3.33, ROI-corrected p = .025) and bilateral 49 
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hippocampus (left peak: x, y, z = -24, -14, -14, Z = 4.38, ROI-corrected p = .002; right peak: 1 
x, y, z = 20, -16, -16, Z = 3.82, ROI-corrected p = .019; Figure 3) in the patient group 2 
compared to control subjects. There were no differences between groups at a whole-brain 3 
level and no significantly reduced activation in patients as compared to control subjects for 4 
the anticipation of dyspnea.  5 
  6 
3.4.3. Associations between brain activation and patient characteristics  7 
Correlation analyses in the patient group revealed that neural activation during dyspnea 8 
anticipation [cue severe vs. cue mild dyspnea] in the left hippocampus was negatively 9 
correlated with 6MWD and positively correlated with mMRC and HADS anxiety scores. 10 
Moreover, peak activations within the right amygdala and right hippocampus were positively 11 
correlated with reduced quality of life (i.e. higher SGRQ scores, Figure 3).  12 
 13 
 14 
#### Figure 3. ##### 15 
 16 
 17 
The lack of differences in brain activation between patient and control group during the 18 
perception of increased dyspnea allowed no offline partial correlation analyses for this 19 
contrast. Instead, explorative post-hoc analyses included the respective patient characteristics 20 
(e.g. disease duration, 6MWD, and scores for SGRQ, mMRC, and HADS anxiety and 21 
depression) as covariates-of-interest within a one-sample model for the patient group. These 22 
analyses revealed a significant positive correlation of disease duration with neural activation 23 
during increased dyspnea [severe vs. mild dyspnea] in the left amygdala (peak: x, y, z = -24, 24 
2, -24, Z = 3.44, ROI-corrected p = .026, Figure 4).  25 
 26 
 27 
##### Figure 4. ##### 28 
 29 
 30 
 31 
4. Discussion 32 
The present fMRI study compared brain activation during the perception and anticipation of 33 
resistive-load induced dyspnea between patients with COPD and matched healthy controls. 34 
Furthermore, we investigated the relationship between COPD-specific brain activation and 35 
patient characteristics.  36 
During the perception of increased dyspnea, patients and control subjects showed widely 37 
comparable neural activation patterns in commonly observed dyspnea-relevant sensorimotor 38 
and cortico-limbic brain regions without significant differences between groups. In contrast, 39 
while anticipating increased dyspnea, enhanced neural activation was observed in patients 40 
relative to control subjects in the bilateral hippocampus and right amygdala. Notably, neural 41 
responses in these emotion-related limbic brain regions were correlated with clinical patient 42 
characteristics. Specifically, patients with higher levels of anxiety and dyspnea as well as 43 
lower exercise capacity showed higher anticipatory neural activation in the left hippocampus, 44 
whereas patients with lower health-related quality of life showed higher anticipatory neural 45 
activity in the right hippocampus and amygdala. Additional explorative findings indicated that 46 
patients with longer disease duration showed higher amygdala activation during the 47 
perception of increasing dyspnea. Taken together, these results suggest that patients with 48 
stable moderate-to-severe COPD show enhanced activation in emotion-related brain areas 49 
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than healthy control subjects during the anticipation, but not during the perception of 1 
experimentally induced increased dyspnea, which further relates to important clinical 2 
characteristics. 3 
 4 
The observed brain activation in sensorimotor (SM1, SII/operculum, SMA, and thalamus) and 5 
cortico-limbic (ACC, insula, and PFC) areas during the perception of increased dyspnea is in 6 
line with previous neuroimaging studies in healthy volunteers (Binks et al., 2014; Evans et al., 7 
2002; McKay et al., 2003; Pattinson et al., 2009; Peiffer et al., 2001; von Leupoldt et al., 8 
2008). Our findings extend the notion of a dual cortical pathway model of dyspnea perception 9 
with pathways subserving either sensorimotor or affective aspects of dyspnea to patients 10 
suffering from COPD (Davenport and Vovk, 2009; von Leupoldt and Dahme, 2005).  11 
Moreover, the present finding that patients and control subjects demonstrated activation in 12 
comparable dyspnea-relevant brain regions corresponds with a recent study by Higashimoto 13 
et al. using near-infrared spectroscopy (Higashimoto et al., 2015). Although limited in spatial 14 
resolution, this study also demonstrated comparable activations in pre-motoric areas between 15 
COPD patients and healthy controls. In addition, several studies on chronic pain syndromes 16 
similarly observed substantial overlap of brain activation during the perception of acute pain 17 
in healthy subjects and patients with several pain conditions (Apkarian et al., 2005, 2011; 18 
Baliki et al., 2006; Derbyshire et al., 2002). However, the absence of enhanced responses in 19 
emotion-related areas during perceived dyspnea in COPD-patients is contrasting with 20 
previous studies on chronic pain conditions such as fibromyalgia, irritable bowel syndrome, 21 
and back pain (Baliki et al., 2006; Hashmi et al., 2013; Jensen et al., 2009). For example, 22 
Hashmi and colleagues (Hashmi et al., 2013) demonstrated a shift towards more activation in 23 
emotion related areas in those patients suffering from lower back pain, who developed 24 
chronicity. The lack of comparable changes in our study might be related to differences 25 
between studies regarding sensory modalities (e.g. thermal pain vs. load induced dyspnea), 26 
experimental designs (with vs. without anticipation conditions; different control conditions), 27 
disease duration, or patient characteristics (see below) including different exacerbations 28 
phenotypes of COPD (Scioscia et al., 2017), which deserves further investigation. 29 
 30 
Importantly, during the anticipation of increased dyspnea, patients with COPD compared to 31 
healthy control subjects showed enhanced neural activation in hippocampus and amygdala, 32 
both key areas in the processing of fear, aversive learning, and pain (LeDoux, 2003; 33 
Sehlmeyer et al., 2009; Wiech and Tracey, 2013). Recent findings in healthy individuals 34 
demonstrated activation of the amygdala during the fearful anticipation of resistive load 35 
induced dyspnea (Stoeckel et al., 2015). Similarly, Apkarian, Hashmi and Baliki (Apkarian et 36 
al., 2011) reported increased amygdala activation prior to a pain stimulus peak in healthy 37 
subjects, indicating a role of the amygdala in the anticipation of impending pain. The 38 
importance of amygdala and hippocampus in pain-related fear acquisition and memory 39 
processes was furthermore confirmed for patients with chronic irritable bowel syndrome 40 
(Icenhour et al., 2015). According to the aforementioned model regarding brain circuitry 41 
involved in the transition from acute to chronic pain (Apkarian et al., 2011; Mansour et al., 42 
2014), the hippocampus and the amygdala are key regions of the limbic circuitry crucially 43 
involved in emotional enhancement processes. This limbic circuitry is presumed to ‘translate’ 44 
sensory signals into more emotional, cognitive suffering states, e.g. by modulating and 45 
amplifying the emotional character of aversive nociceptive input signals over time (Mansour 46 
et al., 2014). Our finding of prominent recruitment of hippocampus and amygdala in COPD 47 
patients during the anticipation of increased dyspnea most likely reflects such an amplified 48 
emotional, in particular more fearful, evaluation of upcoming dyspnea. This might provide, at 49 
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least partly, the neural basis for subsequent fearful avoidance behavior in patients with COPD 1 
and contribute to a spiral of decline in form of activity avoidance, deconditioning, increased 2 
dyspnea and anxiety, and further reductions in quality of life (Reardon et al., 2006; Troosters 3 
et al., 2013). Support for this assumption comes from the present observation that increased 4 
activation of hippocampus and amygdala during increased dyspnea anticipation was closely 5 
related to important clinical characteristics such as reduced exercise capacity and quality of 6 
life as well as higher levels of dyspnea and anxiety. Notably, using structural MRI, 7 
morphological changes of reduced gray matter volume in hippocampus and amygdala were 8 
recently observed in patients with COPD relative to control subjects (Esser et al., 2015), 9 
which further supports the important role of these areas in COPD.  10 
 11 
Finally, post-hoc analyses revealed a positive correlation between disease duration and 12 
amygdala activation during the perception of increased dyspnea. Although explorative in 13 
nature, this finding suggests that the chronic course of COPD results in a functional 14 
modulation of a brain region strongly related to fear and anxiety (LeDoux, 2003; Sehlmeyer 15 
et al., 2009; Wiech and Tracey, 2013). Interestingly, a recent study showed that longer COPD 16 
disease duration was also related to reduced gray matter volume in the ACC (Esser et al., 17 
2015), a key structure for antinociception and the regulation of emotional states that is tightly 18 
interconnected with the amygdala (Tracey and Mantyh, 2007). Given the fact that many 19 
patients with COPD develop comorbid anxiety over time (Maurer et al., 2008; Yohannes and 20 
Alexopoulos, 2014), it might be speculated that this is related to increased amygdala 21 
activation during dyspnea anticipation and perception, paralleled by reduced antinociceptive 22 
ACC capabilities. However, future studies are required directly addressing this assumption.  23 
 24 
When interpreting the present results, several limitations need to be taken into account. We 25 
exclusively studied a small group of highly motivated patients with stable health status and 26 
relatively good physical condition without clinical levels of comorbid anxiety and depression 27 
and no exacerbation history within the last year. This limits the generalizability of our 28 
findings and motivates future studies in other patient populations with larger sample sizes, 29 
different and/or more severe forms of COPD and related comorbidities. Moreover, the use of 30 
resistive-load breathing for the experimental induction of short-lasting dyspnea only mirrors 31 
some aspects of dyspnea, i.e. the sense of increased work and effort of breathing, and might 32 
not be comparable to sustained dyspnea experiences outside the lab. Therefore, future studies 33 
are necessary to extend the present findings to other qualities of dyspnea, for example air 34 
hunger, which might be perceived and/or anticipated differently (Banzett et al., 2008). Finally, 35 
future longitudinal studies are needed to directly address how changes in the neural 36 
processing of perceived and anticipated dyspnea relate to the subsequent development of 37 
activity avoidance, deconditioning, increased dyspnea and anxiety, and reduced quality of life. 38 
 39 
This study suggests that patients with stable moderate-to-severe COPD show enhanced 40 
activation in emotion-related brain areas compared with healthy control subjects during the 41 
anticipation, but not during the perception, of increased resistive-load induced dyspnea. Brain 42 
activation in these areas was related to important clinical characteristics and might contribute 43 
to the development of a downward spiral including fearful activity avoidance, deconditioning, 44 
increased dyspnea and anxiety, and reduced quality of life. Taken together, our findings 45 
contribute to our understanding of brain processes in COPD and their relation with clinical 46 
outcomes and might provide potential targets for future psychological interventions aimed at 47 
improving the burden for patients.  48 
 49 
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Figure legends 1 
  2 
Figure 1 | Diagram of scanning protocol for one trial (out of ten). The entire scan duration 3 
was about 13-17 minutes and differed between participants due to differences in individual 4 
rating speed. 5 
 6 
Figure 2 | Brain activation during the perception of increased dyspnea. (A) Patients with 7 
COPD showed significant activation in the supplementary-motor area (SMA), sensorimotor 8 
cortices (SMC: primary sensorimotor cortex and secondary somatosensory 9 
cortex/operculum), thalamus (Th), anterior cingulate cortex (ACC), dorso-medial prefrontal 10 
cortex (dmPFC), and insula. (B) The control group showed significant activation in 11 
comparable brain areas. (C) The conjunction analysis (patients ∩ control subjects) revealed 12 
shared brain activation during increased dyspnea perception between the patient and control 13 
group. For visual purposes, activation is thresholded at puncorrected < 0.001 with colorbars 14 
indicating T-values.  15 
 16 
Figure 3 | Brain areas with significantly higher neural activation in patients with COPD 17 
compared to the control group during the anticipation of increased dyspnea. (A) Bilateral 18 
hippocampus, (B) right amygdala, and (C) right hippocampus and amygdala. Enhanced neural 19 
activation in these brain regions was correlated with patient characteristics such as reduced 20 
exercise capacity, higher level of dyspnea, and anxiety in the left hippocampus (A), and 21 
reduced quality of life in right hippocampus (B) and right amygdala (C). For visual purposes, 22 
activation is thresholded at puncorrected < 0.001 with colorbars indicating T-values. Significant 23 
correlations are presented as *p < .05, **p < .01, ***p < .001. 24 
 25 
Figure 4 | Positive correlation between left amygdala activation during the perception of 26 
increased dyspnea and disease duration in patients with COPD. For visual purposes, 27 
activation is thresholded at puncorrected < 0.001 with colorbars indicating T-values. Beta weights 28 
(y-axis) of individual subjects’ peak voxel used in the scatter plot indicate neural activation 29 
using arbitrary units. 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
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Tables 1 
   
 COPD  Controls  
   
Subjects, n 17 21 
Females / males, n 8 / 9 11 / 10 
Age, yr. 65.6 (9.3) 63.4 (8.8) 
Height, cm 171.0 (8.2) 173.4 (9.4) 
Weight, kg 75.1 (10.7) 77.5 (13.0) 
Body mass index, kg/m² 25.8 (3.9) 25.7 (3.3) 
FEV1, % predicted 47.2 (10.9) 122.9 (10.3)
*** 
FVC, % predicted 93.1 (12.4) 126.2 (13.0)*** 
FEV1 / FVC, % 41.0 (9.0) 79.8 (4.7)
*** 
Smoking status, %   
- Current smoker 53 %   10 %*** 
- Former smoker 47 %    19 %*** 
- Never smoker - 71 % 
Depression (HADS) 3.2 (2.0)  2.0 (2.2) 
Anxiety (HADS) 3.1 (2.2)  2.1 (2.2) 
Disease severity, n   
- Moderate (GOLD stage II) 4 - 
- Severe (GOLD stage III) 13 - 
Disease duration, years 11.0 (6.2) - 
Exercise capacity (6MWD), m 490 (70) - 
Quality of life (SGRQ) 37.6 (13.5) - 
Level of dyspnea (mMRC) 1.06 (.8) - 
Table 1 | Baseline characteristics. 2 
   
 3 
Abbreviations: FEV1 = forced expiratory volume in 1s; FVC = forced vital capacity; HADS = Hospital Anxiety 4 
and Depression Scale; 6MWD = 6-min-walk distance; SGRQ = St. George’s Respiratory Questionnaire; mMRC 5 
= modified Medical Research Council Dyspnea Scale. 6 
Data are presented as mean (SD). *** p < .001 for the comparison between COPD and control group. 7 
 8 
 9 
20 
 
Table 2 | Resistive load magnitudes and Borg Scale dyspnea ratings. 1 
   
 COPD  Controls  
   
Mild dyspnea   
- Load magnitudes, kPa/l/s .2 (.2)  .3 (.2) 
- Intensity ratings 1.7 (1.1)  .9 (.9)* 
- Unpleasantness ratings 1.9 (1.4)   .9 (.8)** 
Severe dyspnea   
- Load magnitudes, kPa/l/s 2.0 (1.0)   3.3 (1.6)** 
- Intensity ratings 5.1 (1.8) 4.5 (2.4) 
- Unpleasantness ratings 4.9 (2.1) 4.3 (2.5) 
Δ Intensity 3.4 (1.7) 3.6 (1.8) 
Δ Unpleasantness 3.0 (1.6) 3.4 (2.0) 
   
Data are presented as mean (SD). Δ intensity and Δ unpleasantness ratings represent the difference of ratings for 2 
the severe dyspnea condition minus the mild dyspnea condition.  3 
*p < .05, **p < .01 for the comparison between COPD and control group. 4 
 5 
 6 
21 
 
Table 3 | Group means (SD) for Δ respiratory parameters of dyspnea anticipation (cue 1 
severe dyspnea minus cue mild dyspnea) and dyspnea perception (severe dyspnea minus 2 
mild dyspnea) for patients with COPD and control subjects. 3 
      
 Δ anticipation of dyspnea  Δ perception of dyspnea 
    
 COPD Controls  COPD Controls 
      
PETCO2, mmHg -.19 (.92) -.45 (.95)  -.27 (.7) .07 (.56) 
PI, mbar  -.29 (.92) .18 (1.51)  7.48 (4.39) 6.09 (3.37) 
VT, L -.03 (.15) -.03 (.21)  -.1 (.13) -.13 (.26) 
f, breaths/min -.37 (2.07) .23 (1.95)  .13 (1.49) -.59 (1.46) 
VE, L/min -1.1 (.99) -.66 (2.56)  -1.71 (1.1) -2.55 (2.55) 
TI, s .02 (.26) -.13 (.58)  .19 (.21) .27 (.48) 
      
Abbreviations: PETCO2 = partial pressure of end-tidal CO2; PI = Peak inspiratory pressure; VT = Tidal volume; f = 4 
Breathing frequency; VE = Minute ventilation; TI = Inspiratory time. 5 
 6 
 7 
22 
 
Table 4 | MNI-space peak coordinates, z-values, and p-values for regions showing significant 1 
brain activation during increased dyspnea perception in patients with COPD. 2 
 
Brain Region x y z Z p 
        
L SM1 -54 -18 34 5.58 .003† 
R 66 -2 14 4.70 .008* 
L SII/operculum -58 2 12 5.14 .019† 
R 64 6 12 4.89 .001* 
R SMA 10 6 46 4.78 .002* 
L Thalamus -14 -22 -6 3.84 .025* 
L Insular Cortex  
- posterior 
 
-40 
 
-4 
 
-2 
 
4.64 
 
.003* 
- anterior -38 20 2 3.99 .030* 
R 50 10 -6 4.97 .038† 
L ACC  -6 14 28 3.74 .045* 
R PFC  
- dorso-medial 
 
4 
 
20 
 
42 
 
4.40 
 
.009* 
- lateral 24 48 28 4.98 .036† 
L Cerebellum -14 -62 -22 4.95 .040† 
 
Abbreviations: L= left hemisphere; R = right hemisphere; SM1 = primary sensorimotor cortex; SII = secondary 3 
somatosensory cortex; SMA = supplementary-motor area; ACC = anterior cingulate cortex; PFC = prefrontal 4 
cortex. 5 
†whole-brain family-wise error corrected, *corrected for multiple comparisons within respective bilateral ROIs. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
